retatrutide type 2 diabetes phase 2 results 2024 2025 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Retatrutide Phase 3 Updates: Significant

101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com Investor Contact Scott McGowan InvestorBrandNetwork (IBN) Phone: 310.299.1717 [email protected] Investor Website Attachments

Conclusion: Embracing Your Healthier Future, One Bite at a Time Navigating weight management with GLP-1 medications is a journey that combines the power of medical science with the importance of personal habits

GLP-1 microdosing involves using precisely calibrated smaller doses that maintain therapeutic effectiveness while dramatically reducing unwanted side effects

Lower doses produced moderate weight loss Higher doses produced substantially greater reductions Weight loss increased progressively over time A plateau had not clearly been reached at week 48 This suggests potential for continued weight reduction beyond one year, though long-term data remains under investigation

Inositol trials demonstrate improved body composition, with 35% more fat loss and maintained or increased muscle mass (PMID 30915778

She too, got the drug through a compounding pharmacy